Peptide ReadinessJoin the beta
Back to database

FDA APPROVED COMPARATOR

Tesamorelin

Its legitimate FDA indication is routinely extrapolated online into broader body composition and growth hormone claims.

Conceptual three-dimensional molecular signature for Tesamorelin; not an exact chemical structure.
GHRH analogue peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 5 September 2026Evidence grade AAuthorised product precedent
FDA STATUS

FDA approved for a specific US indication

MHRA / UK LICENCE

No UK marketing authorisation identified for the US indication

NICE STATUS

No NICE recommendation identified

NHS ACCESS

No routine NHS access identified

PRIVATE LAWFUL USE CONTEXT

Not a routine licensed UK wellness treatment; US approval does not create a UK licence

EVIDENCE MATURITY

Authorised US evidence for a narrow indication only

DEVELOPMENT PHASE

Authorised product precedent

MARKET EXPOSURE

High research market

PROFESSIONAL RELEVANCE

Keep the approved indication and the limits of extrapolation unmistakable in wellness or combination discussions.

Product, formulation and indication

Egrifta

US · Injection

Reduction of excess abdominal fat in adults with HIV and lipodystrophy

Status history

Production baseline verification recorded.

FDA approved for a narrow specialist indication

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.